Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entospletinib + vincristine
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Entospletinib + vincristine is an experimental combination therapy evaluated for hematological malignancies, notably relapsed or refractory acute lymphoblastic leukemia (ALL). **Entospletinib** is an oral, selective inhibitor of spleen tyrosine kinase (SYK), a crucial component in B-cell receptor signaling pathways. **Vincristine** is a microtubule inhibitor classified as a vinca alkaloid, disrupting mitosis in dividing cells. Combined, these agents aim to synergistically inhibit leukemia cell proliferation and survival. Preclinical studies and early-phase clinical trials suggest enhanced antileukemic efficacy by combining entospletinib with vincristine, particularly in specific genetic subtypes of leukemia such as KMT2A-rearranged ALL[1][4][6].
02
Targets
SYK (Spleen Tyrosine Kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on entospletinib + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entospletinib + vincristine.